The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The American Heart Association recommended eating plant-based proteins and avoiding dairy fat, contradicting recent federal dietary guidance.

Former US Surgeon General Dr Jerome Adams has joined others in criticizing President Donald Trump’s nominee for the role, Dr Casey Means.

Phase 3 studies showed zasocitinib, a highly selective oral tyrosine kinase 2 inhibitor, provided rapid, durable skin improvement.

Intermittent tacrolimus after dupilumab discontinuation in patients with AD was associated with longer time to disease flare than on-demand therapy.

The US Centers for Disease Control temporarily paused more than 24 types of laboratory tests, reportedly because of a routine review.

Adult acne is affected by sedentary behavior, exercise, and sleep, with depression and anxiety having a significant effect on this relationship.

Patients with jDM vs aDM show distinct organ patterns, autoantibody profiles, treatment courses, and outcomes.

A new vaccine from companies Pfizer and Valneva meant to prevent Lyme disease may be one step closer to approval.

The FDA accepts a New Drug Application for bezuclastinib to treat nonadvanced systemic mastocytosis based on positive data from the SUMMIT trial.

Tralokinumab is effective and safe for the treatment of patients with moderate to severe AD through 6 total years of treatment.

Patients with dermatomyositis in the US experience substantial variability in treatment, high glucocorticoid exposure, and significant healthcare utilization.